
Opinion|Videos|September 15, 2023
Available Treatment Options for Patients With Higher-Risk Myelofibrosis
Author(s)Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5







































